Bone biologics appoints healthcare finance veteran robert e. gagnon to board of directors

Burlington, mass.--(business wire)--bone biologics corporation (“bone biologics” or the “company”) (nasdaq: bblg, bblgw), a developer of orthobiologic products for spine fusion markets, today announced that effective immediately robert e. gagnon has been named to the company's board of directors. mr. gagnon fills the seat left by erick lucera, who has resigned effective upon mr. gagnon's appointment. the number of directors of bone biologics remains at four. mr. gagnon is currently chief financ.
BBLG Ratings Summary
BBLG Quant Ranking